The London Goodwin Life Sciences team advised Ducentis BioTherapeutics on its acquisition by Arcutis Biotherapeutics for up to $400 million.
Ducentis BioTherapeutics, a portfolio company of LifeArc Ventures, is a preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases.
Arcutis Biotherapeutics (Nasdaq: ARQT), is a California-based early commercial stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology.
The Goodwin team was led by Graham Defries with support from Kenny Walker-Durrant, Matthew Shelley, Michael Grainger, Heidi Fitchett, Lucy Sharples and George Fagan (Corporate) and Amy Francis (Tax).
For more information please see here.